| October 30, 2017 |
summary |
This study aimed to investigate the effect of calcitriol treatment on non-alcoholic fatty liver disease (NAFLD) patients with different genetic polymorphisms of vitamin D receptor. In a single center randomized double-blind placebo controlled trial; 160 participants aged between 18 and 60 years with hepatic steatosis are treated with Calcitriol (25 µg/day) for 16 weeks. Patients are randomized to receive calcitriol or placebo. Major inclusion criteria include: men and women aged between 18 and 60 years with presence of hepatic steatosis diagnosed by Fibroscan elastography and increased liver enzymes. Major exclusion criteria include: patients with chronic liver diseases, alcohol consumption, hypercalcemia and those receiving hepatotoxic drugs. Intervention: Calcitriol and placebo for 16 weeks. The primary outcome: improvement in serum ALT, AST, GGT. Secondary outcomes are improvement of hepatic steatosis and metabolic component of patients including fasting plasma glucose, LDL, HDL, triglyceride and total cholesterol.
|